Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovaBridge BiosciencesNBP · Entity 6324 | Chief Commercial Officer | July 08, 2026 | July 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovaBridge Biosciences
Report date July 08, 2026 · Filed July 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| 2025 Employee Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.93 · Expires 2036-07-08 | Direct | 949,050 |
Reported balance
After 2026-07-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-08 · Grant · Acquired 949,050 · Balance 949,050 F1: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F2: The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. F3: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS").
F2: The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026.
F3: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 08, 2026 Filed Jul 10, 2026 21:00 UTC | NovaBridge Biosciences NBP · Entity 6324 | Grant2025 Employee Share Option (right to buy) · Derivative | 949,050 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0002126029-26-000003 · form4-07102026_050705.xml · derivative · entry 1 Hagler Mark Arnold · CIK 0002126029 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 949,050 Underlying: Ordinary Shares · 949,050 shares Expires 2036-07-08 F1 · derivative.exercise_price: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F1 · shares: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F2 · derivative.exercise_date: The option vests and becomes exercisable in four equal annual installments beginning on the first anniversary of April 17, 2026. F3 · derivative.underlying: The Ordinary Shares may be represented by ADSs. Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F1 · derivative.underlying_shares: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). F1 · balance_after: Number of underlying securities and exercise price expressed in terms of American Depositary Shares ("ADS"). Read SEC document |
| April 24, 2026 Filed Apr 28, 2026 20:05 UTC | NovaBridge Biosciences NBP · Entity 6324 | PurchaseOrdinary Shares | 230,000 | $2.51 | $577,300.00 |
DisclosureSEC source: 0001193125-26-186924 · ownership.xml · nonDerivative · entry 1 Hagler Mark Arnold · CIK 0002126029 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,000 F1 · security: The Ordinary Shares may be represented by American Depositary Shares ("ADS"). Each 10 ADSs represent 23 Ordinary Shares of the Issuer. F2 · shares: The reported securities are represented by 100,000 ADSs. F3 · price: The price reported in Column 4 is a weighted average price. These ADSs were purchased in multiple transactions at prices ranging from $2.44 to $2.54, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: The reported securities are represented by 100,000 ADSs. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.